Clinical Trials
172
Trial Phases
6 Phases
Drug Approvals
231
Drug Approvals
Efavirenz，Lamivudine and Tenofovir Disoproxil Fumarate Tablets（I）
- Product Name
- 依非米替片(Ⅰ)
- Approval Number
- 国药准字HJ20220093
- Approval Date
- Nov 30, 2022
Clinical Trials
Distribution across different clinical trial phases (170 trials with phase data)• Click on a phase to view related trials
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
- Conditions
- Female Contraception
- Interventions
- Drug: Transdermal system containing progestin
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 1500
- Registration Number
- NCT06672016
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸SEC Clinical Research, Dothan, Alabama, United States
🇺🇸AMR Mobile, Mobile, Alabama, United States
Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch
- Conditions
- Contraception
- Interventions
- Drug: MR-130A-01 Transdermal patch
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 168
- Registration Number
- NCT06048536
- Locations
- 🇩🇪
dinox GmbH, Berlin, Germany
Extension Study of MYL-1701P-3001 for Safety and Efficacy
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 52
- Registration Number
- NCT04674800
- Locations
- 🇮🇳
Mylan Investigative site, New Delhi, India
🇮🇳Mylan Investigative Site, Noida, Uttar Pradesh, India
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
- Conditions
- NSCLC Stage IV
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 671
- Registration Number
- NCT04633564
- Locations
- 🇧🇾
Grodno Clinical Regional Hospital, Mogilev, Belarus
🇧🇾Mogilev Regional Oncology Dispensary, Minsk, Minskaya Voblasts, Belarus
🇧🇾Babruysk Interregional Oncological Dispensary, Babruysk, Belarus
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 355
- Registration Number
- NCT03610646
- Locations
- 🇷🇺
Mylan Investigator Site, Saint Petersburg, Russian Federation
🇮🇳Mylan Investigator site, Bangalore, Karnataka, India
🇯🇵National Hospital Organization Osaka National Hospital, Osaka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 32
- Next
News
Bausch Health and Mylan Reach Settlement Agreement Over Generic IBS Drug Patents
Bausch Health Companies Inc. and Mylan Pharmaceuticals have reached a settlement agreement resolving their patent litigation over generic versions of irritable bowel syndrome (IBS) medications.
Heron Therapeutics Settles Patent Litigation with Mylan for CINVANTI and APONVIE
Heron Therapeutics has reached a settlement agreement with Mylan Pharmaceuticals to resolve ongoing patent litigations related to CINVANTI and APONVIE injectable emulsions.
Federal Circuit Upholds Regeneron's Preliminary Injunction Against Samsung Bioepis in EYLEA Patent Dispute
The Federal Circuit affirmed a preliminary injunction against Samsung Bioepis, preventing the sale of its biosimilar version of Regeneron's EYLEA (aflibercept) in the United States.
Glenmark Launches Generic Clindamycin Phosphate Foam for Dermatological Treatment
Glenmark Pharmaceuticals Inc., USA has introduced Clindamycin Phosphate Foam 1%, a bioequivalent generic version of Evoclin® Foam, expanding their dermatology portfolio.